NCT05064280View on ClinicalTrials.gov

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Brain MetastasesTumor
Interventions
DRUG

Pembrolizumab

Given by IV (200 mg IV D1 Q3W)

DRUG

Lenvatinib

Given by PO (20 mg PO QD)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER